• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care

    2/4/25 11:27:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • New survey shows 40% of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma1
    • 70% of people with diabetes said supportive comments from others can significantly boost their motivation to manage their condition1
    • Abbott launches film that highlights challenges of living life with diabetes

    ABBOTT PARK, Ill., Feb. 4, 2025 /PRNewswire/ -- 'One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have diabetes.' New survey results and a film released today by Abbott highlight how everyday comments like these may affect people living with diabetes.

    Experience the full interactive Multichannel News Release here: https://www.multivu.com/abbott/9294252-en-abbott-above-the-bias-film-aims-to-reduce-stigma-about-diabetes

    People living with diabetes – which now includes 1 in 6 adults in America2 – face many barriers to receiving care. Survey data reveal that the misconceptions and stereotypes around the condition can weigh heavily on the minds of those living with diabetes, creating one more barrier and potentially preventing them from managing their health.1

    "How many times have we heard 'That looks like diabetes on a plate' when we're watching a movie, eating at a restaurant or scrolling through social media?," said Dr. Susan Guzman, Behavioral Diabetes Institute co-founder, clinical psychologist, and diabetes specialist. "After more than two decades of research and working with people managing diabetes, I can tell you that misconceptions around diabetes take a real toll on people. If we want to help people have healthier lives, we have to recognize where and how bias around diabetes exists and promote a compassionate and fact-based understanding of diabetes."

    Data1 from a survey of more than 2,600 people living with diabetes across eight countries, including the U.S., highlights they may not be getting the care they need due to the shame and stigma around their condition, which can lead to real and often unnoticed health consequences:

    • Diabetes Stigma is an Issue: Nearly 70% believe there is stigma associated with their condition.1
    • Diabetes as a Punchline: 85% of people living with diabetes say they have seen inaccuracies about diabetes in the media, including on TV shows, movies, and social media, and 40% of people felt that diabetes is often used as the punchline of a joke.1
    • Shame Causes Silence: Almost 25% have avoided sharing their diagnosis with family or friends out of embarrassment or concern.1
    • Health Consequences: 40% have skipped or missed a doctor's appointment due to shame or stigma.1

    Additional biometric testing revealed that nearly 40% of individuals had an elevated physiological response to stigmatizing statements, even if they don't show outward signs or expressions.1

    • Food Elicits the Most Significant Response: The question, "Should you really be eating that?" prompted the strongest biometric response, causing elevated heart rate and increased perspiration — similar to the stress of a job interview or a first date.1

    But while words can hurt, they can also help.

    • Support Leads to Progress: The survey also revealed nearly 70% believe supportive comments from others can significantly boost their motivation to manage their condition.1

    Above the Bias

    Abbott's new Above the Bias initiative aims to help others see the world from the perspective of someone living with diabetes. The initiative builds upon efforts by several diabetes organizations, patient advocacy groups, and experts that continue to work to reduce stigma about diabetes.3 People can learn more about Above the Bias and watch the film at AboveBias.com.

    "From the very early days of Libre, it's been our job to make living with diabetes easier," said Chris Scoggins, executive vice president of Abbott's diabetes care business. "But technology alone can't fix every barrier that people face. We're committed to doing our part, but we can't do it alone. We need the ongoing help of others to support people living with diabetes, so they can get the care they need to manage their health."

    About FreeStyle Libre:

    Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading FreeStyle Libre continuous glucose monitoring portfolio, which today is used by about 7 million people in more than 60 countries.4 People use Libre to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals.

    About Abbott:

    Abbott is a global healthcare leader and continues to pioneer ground-breaking technology and initiatives to support people live more fully at all stages of life. The company revolutionized diabetes care 10 years ago with its world-leading Libre continuous glucose monitoring portfolio, which today is used by 7 million people in more than 60 countries.4 Abbott's other technologies span the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at Abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    Abbott Media:

    Katie Walker, [email protected]

    Abbott Financial:

    Michael Comilla, [email protected]

    Product for prescription only; for Important Safety Information, please visit FreeStyleLibre.us.

    1. Data on file. Research conducted by Savanta on behalf of Abbott between May and August 2024 was executed in three distinct phases among people with diabetes across Canada, France, Germany, Ireland, Italy, Japan, the UK, and the U.S.
    2. National Diabetes Statistics Report, U.S. Centers for Disease Control and Prevention: National Diabetes Statistics Report | Diabetes | CDC
    3. J. Speight, E. Holmes-Truscott, M. Garza et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Published January 2024. DOI: https://doi.org/10.1016/S2213-8587(23)00347-9
    4. Data on File. Abbott Diabetes Care.
    Still image from Abbott's Above the Bias film.

     

    Cision View original content:https://www.prnewswire.com/news-releases/abbotts-above-the-bias-film-reveals-misconceptions-can-impact-diabetes-care-302367723.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Orville Jacob A

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    3/25/26 6:56:57 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Orville Jacob A

    3 - ABBOTT LABORATORIES (0000001800) (Issuer)

    3/25/26 6:46:39 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior Vice President Shroff Eric covered exercise/tax liability with 1,384 units of Common shares without par value and sold $81,946 worth of Common shares without par value (709 units at $115.58), decreasing direct ownership by 5% to 39,164 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    3/3/26 8:20:08 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

    Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+Learn more at Cologuard.com/TheTalkABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is reuniting beloved sitcom family members, John Stamos and Jodie Sweetin, for "The (Second) Talk" campaign – because when it comes to colon cancer screening, even adults need another trusted adult for advice."The (Second) Talk," brings back TV's favorite uncle and niece duo to spoof "the talk" for a nostalgic, sitcom-style skit to remind people that while colon ca

    3/24/26 8:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott completes acquisition of Exact Sciences

    Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea

    3/23/26 8:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    SEC Filings

    View All

    SEC Form S-8 filed by Abbott Laboratories

    S-8 - ABBOTT LABORATORIES (0000001800) (Filer)

    3/23/26 5:30:42 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    3/23/26 8:54:17 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Abbott Laboratories

    DEFA14A - ABBOTT LABORATORIES (0000001800) (Filer)

    3/13/26 4:01:21 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott completes acquisition of Exact Sciences

    Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea

    3/23/26 8:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care